Unione Europea - italiano - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - adalimumab - spondylitis, ankylosing; arthritis, juvenile rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; arthritis, rheumatoid - immunosoppressori - si prega di fare riferimento al documento informativo del prodotto.

Unione Europea - italiano - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - linaclotide - sindrome dell'intestino irritabile - farmaci per la stitichezza - constella è indicato per il trattamento sintomatico della sindrome da irritazione intestinale da moderata a grave con stitichezza (ibs-c) negli adulti.

Unione Europea - italiano - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - glecaprevir, pibrentasvir - epatite c, cronica - antivirali per uso sistemico - maviret is indicated for the treatment of chronic hepatitis c virus (hcv) infection in adults and children aged 3 years and older. maviret coated granules is indicated for the treatment of chronic hepatitis c virus (hcv) infection in children 3 years and older.

Unione Europea - italiano - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - agenti antineoplastici - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.

Unione Europea - italiano - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - bimatoprost timolol - glaucoma, open-angle; ocular hypertension - oftalmologici - riduzione della pressione intraoculare (iop) nei pazienti con glaucoma ad angolo aperto o ipertensione oculare che non rispondono in modo adeguato ai beta-bloccanti topici o agli analoghi delle prostaglandine.

Unione Europea - italiano - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - bimatoprost - glaucoma, open-angle; ocular hypertension - prostaglandin analogues, ophthalmologicals - riduzione della pressione intraoculare elevata nel glaucoma cronico ad angolo aperto ed ipertensione oculare (come monoterapia o come terapia aggiuntiva ai beta-bloccanti).

Unione Europea - italiano - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - ombitasvir, paritaprevir, ritonavir - epatite c, cronica - antivirali per uso sistemico - viekirax è indicato in associazione con altri medicinali per il trattamento dell'epatite cronica c (chc) negli adulti. per il virus dell'epatite c (hcv) di genotipo specifico l'attività.

Unione Europea - italiano - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - immunosoppressori - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Unione Europea - italiano - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - atogepant - emicrania - aquipta is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.

Unione Europea - italiano - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - venetoclax - leucemia, linfocitica, cronica, b-cell - agenti antineoplastici - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.